Pamiparib
- Product Name
- Pamiparib
- CAS No.
- 1446261-44-4
- Chemical Name
- Pamiparib
- Synonyms
- Pamiparib;bgb-290;EOS-61090;BGB-290,Pamiparib;Pamiparib(BGB290);Alflutinib Impurity 17;Pamiparib, 10 mM in DMSO;PAMIPARIB; BGB-290; BGB 290; BGB290.;inhibit,Pamiparib,PARP,Inhibitor,poly ADP ribose polymerase,BGB 290,BGB290;(R)-2-fluoro-10a-methyl-5,8,9,10,10a,11-hexahydro-5,6,7a,11-tetraazacyclohepta[def]cyclopenta[a]fluoren-4(7H)-one
- CBNumber
- CB13137483
- Molecular Formula
- C16H15FN4O
- Formula Weight
- 298.31
- MOL File
- 1446261-44-4.mol
Pamiparib Property
- Density
- 1.68±0.1 g/cm3(Predicted)
- storage temp.
- Store at -20°C
- solubility
- DMF:20.0(Max Conc. mg/mL);67.04(Max Conc. mM)
DMF:PBS (pH 7.2) (1:10):0.09(Max Conc. mg/mL);0.3(Max Conc. mM)
DMSO:40.83(Max Conc. mg/mL);136.88(Max Conc. mM)
Ethanol:45.0(Max Conc. mg/mL);150.84(Max Conc. mM) - form
- A solid
- pka
- 11.56±0.40(Predicted)
- color
- Light yellow to yellow
- InChI
- InChI=1S/C16H15FN4O/c1-16-3-2-4-21(16)7-11-13-12-9(15(22)20-19-11)5-8(17)6-10(12)18-14(13)16/h5-6,18H,2-4,7H2,1H3,(H,20,22)/t16-/m1/s1
- InChIKey
- DENYZIUJOTUUNY-MRXNPFEDSA-N
- SMILES
- N1C2=C3C(C(=O)NN=C4C3=C1[C@@]1(C)CCCN1C4)=CC(F)=C2
Hazard and Precautionary Statements (GHS)
- Symbol(GHS)
-
- Signal word
- Danger
- Hazard statements
-
H226Flammable liquid and vapour
H314Causes severe skin burns and eye damage
- Precautionary statements
-
P210Keep away from heat/sparks/open flames/hot surfaces. — No smoking.
P233Keep container tightly closed.
P240Ground/bond container and receiving equipment.
P241Use explosion-proof electrical/ventilating/lighting/…/equipment.
P242Use only non-sparking tools.
P243Take precautionary measures against static discharge.
P260Do not breathe dust/fume/gas/mist/vapours/spray.
P262Do not get in eyes, on skin, or on clothing.
P264Wash hands thoroughly after handling.
P264Wash skin thouroughly after handling.
P270Do not eat, drink or smoke when using this product.
P271Use only outdoors or in a well-ventilated area.
P280Wear protective gloves/protective clothing/eye protection/face protection.
P284Wear respiratory protection.
P301+P330+P331IF SWALLOWED: Rinse mouth. Do NOT induce vomiting.
P303+P361+P353IF ON SKIN (or hair): Remove/Take off Immediately all contaminated clothing. Rinse SKIN with water/shower.
P370+P378In case of fire: Use … for extinction.
P403+P233Store in a well-ventilated place. Keep container tightly closed.
P403+P235Store in a well-ventilated place. Keep cool.
P405Store locked up.
P501Dispose of contents/container to..…
N-Bromosuccinimide Price
- Product number
- CS-0027388
- Product name
- Pamiparib
- Purity
- 99.97%
- Packaging
- 5mg
- Price
- $90
- Updated
- 2021/12/16
- Product number
- CS-0027388
- Product name
- Pamiparib
- Purity
- 99.97%
- Packaging
- 10mg
- Price
- $150
- Updated
- 2021/12/16
- Product number
- CS-0027388
- Product name
- Pamiparib
- Purity
- 99.97%
- Packaging
- 25mg
- Price
- $250
- Updated
- 2021/12/16
- Product number
- CS-0027388
- Product name
- Pamiparib
- Purity
- 99.97%
- Packaging
- 50mg
- Price
- $450
- Updated
- 2021/12/16
- Product number
- CS-0027388
- Product name
- Pamiparib
- Purity
- 99.97%
- Packaging
- 100mg
- Price
- $750
- Updated
- 2021/12/16
Pamiparib Chemical Properties,Usage,Production
Description
Pamiparib (BGB-290) is an investigational small molecule inhibitor of PARP1 and PARP2. Pamiparib is being evaluated as a monotherapy in pivotal clinical trials in China in recurrent platinum-sensitive and BRCA1/2 mutated ovarian cancers.
Uses
Pamiparib, is a PARP inhibitor, which can be used as an anticancer agent.
Mechanism of action
Pamiparib inhibits the activity of PARP enzymes, interfering with the DNA damage repair mechanism of tumor cells, especially in those cancer cells with BRCA gene mutations, which have become dependent on the PARP-mediated repair pathway to maintain the stability of their genome. Therefore, pamiparib can increase DNA damage in these tumor cells, leading to tumor cell death.
Synthesis
Using 2-bromo-5-fluorobenzoic acid (27.1) as the raw material, a series of reactions were performed to obtain methyl benzoate 27.2, which was then reduced and protected to obtain the key aromatic bromide fragment 27.3. Using pyrrolene 27.4 as the raw material, alkane 27.8 was obtained by reaction with tert-butyl bromoacetate 27.5, addition of acetylene group, removal of silicon group, etc., and then enantiomer separation was performed to obtain the desired (R)-enantiomer 27.10. The alkynyl group 27.10 and the bromide group 27.3 were subjected to Larock heterocyclization reaction to generate indole 27.11, which was then treated with trifluoromethanesulfonic acid and hydrazine hydrate reaction to finally obtain Pamiparib (27) as a semihydrate crystalline solid with a yield of 50%.
in vivo
Oral administration of Pamiparib results in time-dependent and dose-dependent inhibition of PARylation in MDA-MB-436 (BRCA1 mutant) breast cancer xenograft, correlating well with the tumor drug concentrations. It has also demonstrated good combination activity with chemotherapeutics in patient biopsy derived SCLC models. Also Pamiparib has significant brain penetration in C57 mice. The drug exposure in brain vs. that in plasma was close to 20% after oral administration of BGB-290.
IC 50
PARP